Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 95 clinical trials
  • 0 views
  • 19 Dec, 2020
  • 364 locations
Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.

This is a randomized phase 3 trial aiming to compare the efficacy of docetaxel and hormone therapy as second line treatment in patients with mCRPC progressing after therapy with abiraterone or

  • 0 views
  • 23 Jan, 2021
  • 2496 views
  • 01 Jan, 2021
  • 210 locations
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

D will receive pembrolizumab + abiraterone + prednisone Cohort E will receive pembrolizumab+lenvatinib, Cohort F will receive pembrolizumab+lenvatinib, Cohort G will receive MK-7684A, Cohort H will

bone lesions
solid tumour
cancer progression
soft tissue disease
metastasis
  • 0 views
  • 12 Dec, 2020
  • 11 locations
Investigation of Radium-223 Dichloride (Xofigo) a Treatment That Gives Off Radiation That Helps Kill Cancer Cells Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

study will be either abiraterone acetate (Zytiga) (plus prednisone/prednisolone) or enzalutamide (Xtandi). Both of them are standard approved medications which are used in the treatment of advanced

  • 0 views
  • 01 Jan, 2021
  • 140 locations
Abiraterone Acetate in Combination With Tildrakizumab

The purpose of this study is to find out the side effects and safety of a combination of the anti-IL23 targeting monoclonal antibody tildrakizumab in combination with abiraterone acetate in men

  • 0 views
  • 04 Jan, 2021
  • 7 locations
A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC

The aim of this trial is to evaluate the Drug-Drug interaction with Abiraterone combined with SHR3162 in the Metastatic Castration Resistant Prostate Cancer Patients.

  • 0 views
  • 23 Jan, 2021
  • 1 location
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Abiraterone Acetate

This is a pilot phase 2 single-arm study, of men with metastatic castration-resistant prostate cancer (mCRPC). Patients will be treated with abiraterone acetate 1000 mg daily plus prednisone 5

luteinizing hormone
platelet count
bone scan
soft tissue disease
neutrophil count
  • 0 views
  • 25 Jan, 2021
  • 1 location
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

while receiving abiraterone acetate (abiraterone) and prednisone therapy, and to observe the effects of Onvansertib in combination with abiraterone and prednisone on disease control.

liver metastases
hormone therapy
bone scan
neutrophil count
endocrine therapy
  • 1 views
  • 04 Dec, 2020
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • 0 views
  • 17 Dec, 2020
  • 3 locations